LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer
| العنوان: | LMTK2 as Potential Biomarker for Stratification between Clinically Insignificant and Clinically Significant Prostate Cancer |
|---|---|
| المؤلفون: | Kestutis Suziedelis, Feliksas Jankevičius, Marius Kincius, Albertas Ulys, Julija Simiene, Alvydas Vezelis, Daiva Dabkeviciene, Sonata Jarmalaite |
| المصدر: | Journal of Oncology, Vol 2021 (2021) Journal of Oncology Journal of oncology, London : Hindawi, 2021, vol. 2021, art. no. 8820366, p. 1-6 |
| بيانات النشر: | Hindawi Limited, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Prostate biopsy, Article Subject, Urology, Disease, urologic and male genital diseases, LMTK2, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Polymorphism (computer science), Genotype, medicine, MSMB, RC254-282, medicine.diagnostic_test, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Potential biomarkers, business, Research Article |
| الوصف: | A set of prostate tumors tend to grow slowly and do not require active treatment. Therefore, stratification between patients with clinically significant and clinically insignificant prostate cancer (PC) remains a vital issue to avoid overtreatment. Fast development of genetic technologies accelerated development of next-generation molecular tools for reliable PC diagnosis. The aim of this study is to evaluate the diagnostic value of molecular biomarkers (CRISP3, LMTK2, and MSMB) for separation of PC cases from benign prostatic changes and more specifically for identification of clinically significant PC from all pool of PC cases in patients with rising PSA levels. Patients (n = 200) who had rising PSA (PSA II) after negative transrectal systematic prostate biopsy due to elevated PSA (PSA I) were eligible to the study. In addition to PSA concentration, PSA density was calculated for each patient. Gene expression level was measured in peripheral blood samples of cases applying RT-PCR, while MSMB (−57 C/T) polymorphism was identified by pyrosequencing. LMTK2 and MSMB significantly differentiated control group from both BPD and PC groups. MSMB expression tended to increase from the major alleles of the CC genotype to the minor alleles of the TT genotype. PSA density was the only clinical characteristic that significantly differentiated clinically significant PC from clinically insignificant PC. Therefore, LMTK2 expression and PSA density were significantly distinguished between clinically significant PC and clinically insignificant PC. PSA density rather than PSA can differentiate PC from the benign prostate disease and, in combination with LMTK2, assist in stratification between clinically insignificant and clinically significant PC. |
| وصف الملف: | application/pdf; text/xhtml |
| اللغة: | English |
| تدمد: | 1687-8469 1687-8450 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c730670a4805d9c231c8fa81524594Test https://doaj.org/article/bb4f2f66cd9e4bb39eb8fe6d31d945b4Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....95c730670a4805d9c231c8fa81524594 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16878469 16878450 |
|---|